keyword
MENU ▼
Read by QxMD icon Read
search

cutaneous adverse effects, drug

keyword
https://www.readbyqxmd.com/read/27922065/detc-based-bacterial-cellulose-bio-curatives-for-topical-treatment-of-cutaneous-leishmaniasis
#1
Fabiana S Celes, Eliane Trovatti, Ricardo Khouri, Johan Van Weyenbergh, Sidney J L Ribeiro, Valeria M Borges, Hernane S Barud, Camila I de Oliveira
The treatment of leishmaniasis still relies on drugs with potentially serious adverse effects. Herein, we tested a topical formulation of bacterial cellulose (BC) membranes containing Diethyldithiocarbamate (DETC), a superoxide dismutase 1 inhibitor. Leishmania-infected macrophages exposed to BC-DETC resulted in parasite killing, without pronounced toxic effects to host cells. This outcome was associated with lower SOD1 activity and higher production of superoxide and cytokine mediators. Topical application of BC-DETC significantly decreased lesion size, parasite load and the inflammatory response at the infection site, as well as the production of both IFN-γ and TNF...
December 6, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27916918/subchronic-toxicities-of-hz1006-a-hydroxamate-based-histone-deacetylase-inhibitor-in-beagle-dogs-and-sprague-dawley-rats
#2
Xiaofang Zhang, Xiaodong Zhang, Bojun Yuan, Lijun Ren, Tianbao Zhang, Guocai Lu
Histone deacetylase inhibitors (HDACIs), such as vorinostat and panobinostat, have been shown to have active effects on many hematologic malignancies, including multiple myeloma and cutaneous T-cell lymphoma. Hydroxamate-based (Hb) HDACIs have very good toxicity profiles and are currently being tested in phases I and II clinical trials with promising results in selected neoplasms, such as bladder carcinoma. One of the Hb-HDACIs, HZ1006, has been demonstrated to be a promising drug for clinical use. The aim of our study was to determine the possible target of toxicity and to identify a non-toxic dose of HZ1006 for clinical use...
November 30, 2016: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/27898459/characterization-of-the-adverse-effects-induced-by-acetaminophen-and-non-steroidal-anti-inflammatory-drugs-based-on-the-analysis-of-the-japanese-adverse-drug-event-report-database
#3
Junko Nagai, Yoshihiro Uesawa, Ryotaro Shimamura, Hajime Kagaya
OBJECTIVES: Acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are antipyretic analgesics with established adverse effects; however, only a few studies have compared their adverse effects simultaneously. We aimed to compare the adverse effects of these medications to confirm the respective frequencies of both rare and major adverse effects. METHODS: We used a high-quality database for spontaneous adverse drug event reporting in Japan. Data were extracted regarding the adverse effects of acetaminophen and NSAIDs to compare the tendency of the appearance of those adverse effects between the drugs...
November 24, 2016: Clinical Journal of Pain
https://www.readbyqxmd.com/read/27885401/-cutaneous-side-effects-of-targeted-cancer-drugs
#4
REVIEW
J Below, B Homey, P A Gerber
In the past decades many new drugs were approved for the treatment of cancer and have been established as essential parts of various therapeutic regimens. In particular targeted therapies and immune checkpoint inhibitors that aim at specific carcinogenic signaling pathways or modulate the tumor-immune response have revolutionized cancer therapy. Despite their targeted actions, these drugs may lead to diverse adverse reactions. In particular, cutaneous toxicities represent a serious threat to patients' quality of life and may lead to dose reduction or therapy cessation...
November 24, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27860166/treatment-of-antiviral-resistant-recurrent-erythema-multiforme-with-dapsone
#5
Allen S W Oak, Lucia Seminario-Vidal, Naveed Sami
Recurrent erythema multiforme (REM) is a chronic disease characterized by frequent episodes of target cutaneous lesions in an acral distribution. Conventional treatment includes systemic corticosteroids and antiviral therapy. The aim of this study was to evaluate dapsone as a potential steroid sparing-agent for the treatment of REM after a failed trial of at least one antiviral therapy (acyclovir, famciclovir, or valacyclovir). A retrospective chart review was conducted on thirteen patients with a diagnosis of REM who underwent treatment with dapsone after failing at least one antiviral therapy...
November 18, 2016: Dermatologic Therapy
https://www.readbyqxmd.com/read/27853063/successful-re-administration-of-low-dose-of-methimazole-mmi-in-graves-disease-patients-who-experienced-allergic-cutaneous-reactions-to-mmi-at-initial-treatment-and-had-received-long-term-propylthiouracil-ptu
#6
Sumihisa Kubota
Objective When patients with Graves' disease show severe allergic cutaneous reactions, physicians often suggest that they undergo radioiodine therapy instead of receiving propylthiouracil (PTU), another antithyroid drug, because anti-neutrophil cytoplasmic antibody (ANCA) -related vasculitis can occur with PTU, especially with long-term use. However, some patients refuse radioiodine therapy and chose PTU. Sometimes PTU treatment may be prolonged. Since the frequency of adverse effects of methimazole (MMI) is dose-related, there is a possibility that we can re-administer a low dose without adverse effects to patients well-controlled with PTU who once experienced an allergic reaction to MMI...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27835909/impact-of-hla-b-58-01-allele-and-allopurinol-induced-cutaneous-adverse-drug-reactions-evidence-from-21-pharmacogenetic-studies
#7
Ran Wu, Yi-Ju Cheng, Li-Li Zhu, Lei Yu, Xue-Ke Zhao, Min Jia, Chang-Hui Wen, Xing-Zhen Long, Ting Tang, Ai-Juan He, Yi-Yan Zeng, Zun-Feng Ma, Zhi Zheng, Mu-Zi Ni, Gong-Jing Cai
Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). Recently, HLA-B*58:01 allele was identified as a strong genetic marker for allopurinol-induced CADRs in Han Chinese. However, the magnitude of association and diagnosis value of HLA-B*58:01 in allopurinol-induced CADRs remain inconclusive. To investigate this inconsistency, we conducted a meta-analysis of 21 pharmacogenetic studies, including 551 patients with allopurinol-induced CADRs, and 2,370 allopurinol-tolerant controls as well as 9,592 healthy volunteers...
November 9, 2016: Oncotarget
https://www.readbyqxmd.com/read/27828640/alemtuzumab-in-refractory-s%C3%A3-zary-syndrome
#8
Carmen María Alcántara Reifs, Rafael Salido-Vallejo, Gloria María Garnacho-Saucedo, Sofía De la Corte-Sánchez, Alberto González-Menchen, Antonio Vélez García-Nieto
Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/27791234/cutaneous-toxicity-from-epidermal-growth-factor-receptor-inhibitors-would-a-subcutaneous-desensitization-be-helpful-case-report
#9
Andrea D'Alessio, Sara Cecchini, Daniela Di Mauro, Luca Geroli, Simonetta Villa, Antonello Quadri, Davide Resta, Carmelo Fortugno
PURPOSE: Cetuximab and panitumumab are monoclonal antibody inhibitors that bind the epidermal growth factor receptor (EGFR) currently used in the treatment of metastatic colorectal cancer. The main adverse event related to EGFR inhibitors (EGFR-Is) is cutaneous toxicity, which can cause dosage reduction and interruption of treatment. State-of-the-art management of skin toxicity associated with EGFR-Is therapy involves the topical administration of corticosteroids and oral antibiotics, but is not completely effective in the management of toxicity...
October 26, 2016: Tumori
https://www.readbyqxmd.com/read/27779083/severe-drug-hypersensitivity-reactions-clinical-pattern-diagnosis-etiology-and-therapeutic-options
#10
Maren Paulmann, Maja Mockenhaupt
Severe cutaneous adverse reactions (SCAR) are known for a high morbidity and mortality. They may be life-threatening for the affected patient and difficult to accomplish for the patient's family and the treating physician. Such conditions include not only bullous reactions like toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), but also acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS). Since clinical pattern, etiology, prognosis and treatment differ among these severe skin reactions, a clear diagnosis based on a comprehensive clinical examination, skin biopsy, and specific laboratory tests is necessary...
September 28, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27764805/nivolumab-for-advanced-melanoma-pretreatment-prognostic-factors-and-early-outcome-markers-during-therapy
#11
Yoshio Nakamura, Shigehisa Kitano, Akira Takahashi, Arata Tsutsumida, Kenjiro Namikawa, Keiji Tanese, Takayuki Abe, Takeru Funakoshi, Noboru Yamamoto, Masayuki Amagai, Naoya Yamazaki
BACKGROUND: An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already been described as prognostic factors for advanced melanoma treated with nivolumab. We sought to identify further clinical predictors that can be determined in routine clinical practice. METHODS: We retrospectively analyzed clinical findings of 98 consecutive patients with unresectable stage III or IV melanoma treated with nivolumab, at the National Cancer Center Hospital or at Keio University Hospital, in Tokyo, Japan, between July 2014 and July 2016...
October 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27749688/hla-a-02-alleles-are-associated-with-tetanus-antitoxin-induced-exanthematous-drug-eruptions-in-chinese-patients
#12
Sijia Yan, Sheng-An Chen, Wen Zhang, Fanping Yang, Ying Yang, Qinyuan Zhu, Huizhong Zhu, Xinfen Sun, Menglin Jiang, Yu Su, Lirong Zhang, Qinghe Xing, Xiaoqun Luo
OBJECTIVE: Tetanus antitoxin (TAT) is an effective antitetanus medicine, but may sometimes cause adverse drug reactions such as rapid-onset anaphylactic shock and late-onset cutaneous adverse drug reactions, including exanthematous drug eruptions (EDE). Human leukocyte antigen (HLA) class I alleles are strongly associated with different types of cutaneous adverse drug reactions. This study aimed to assess whether there is an association between TAT-induced EDE and HLA-A, HLA-B, and HLA-C alleles in the Chinese Han population...
October 5, 2016: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/27741338/75-complete-response-and-15-partial-response-to-extracorporeal-photopheresis-combined-with-other-therapies-in-resistant-early-stage-cutaneous-t-cell-lymphoma
#13
Sila Seremet, Sunil Abhyankar, Tiffany J Herd, Daniel Aires
INTRODUCTION: Extracorporeal photopheresis (ECP) has been used for the treatment of advanced stage or treatment refractory cutaneous T-cell lymphoma (CTCL) since 1987, and more recently has also been shown to be of benefit for earlier stage resistant CTCL. Complete response rates in prior studies of ECP in early CTCL have ranged from 0% to 40%. METHODS: We reviewed electronic medical records of all CTCL patients seen in the University of Kansas Cancer Center between June 2007 and May 2011...
October 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27741337/therapeutic-synergy-neutrality-and-antagonism-combination-treatment-in-dermatology
#14
Mark A Strom, Girish C Mohan, Peter A Lio
Dermatologists frequently employ combination therapy to treat various diseases, but the evidence to support the use of such combinations is often lacking. Synergy is an appealing although somewhat ambiguous concept in medicine. Utilizing synergy allows clinicians to provide the most efficacious combination of treatments to patients, while potentially minimizing adverse effects and reducing the development of drug resistance. Definitions of synergy vary, but ultimately converge on finding a therapeutic advantage in combining treatments...
October 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27741336/bensal-hp-for-second-intention-healing-following-mohs-micrographic-surgery-or-shave-skin-biopsy-an-open-label-pilot-study
#15
Breanne Mordorski, Adam J Friedman, Leon H Kircik
Dermatologists frequently create cutaneous defects that heal by second intention, yet there is no universal protocol for wound care in this setting. Several ointments commonly used for wound healing are not cost effective as they contain known contact allergens, contribute to antimicrobial resistance, and do not enhance the healing process. Recent studies indicate that Bensal HP, a commercially available ointment used for a variety of dermatologic conditions, may be useful for wound healing; although clinical data is currently limited...
October 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27725919/afatinib-associated-cutaneous-toxicity-a-correlation-of-severe-skin-reaction-with-dramatic-tumor-response-in-a-woman-with-exon-19-deletion-positive-non-small-cell-lung-cancer
#16
Lindsay P Osborn, Philip R Cohen
Epidermal growth factor receptor (EGFR) inhibitors are biological factors used in the treatment of non-small-cell lung cancers (NSCLC) that are positive for EGFR mutations. Afatinib is one such drug that has been approved for use in this capacity. Cutaneous toxicity is the second most commonly reported adverse event with the use of afatinib. A 39-year-old woman with inoperative right lung adenocarcinoma was initially treated with afatinib. She not only developed a severe papulopustular eruption but also had a dramatic reduction of her tumor...
September 1, 2016: Curēus
https://www.readbyqxmd.com/read/27723197/therapeutic-hotline-oral-allicin-in-the-treatment-of-behcet-s-disease-through-attenuating-oxidative-stress-a-pilot-study-in-20-patients-with-mucocutaneous-lesions
#17
Jianqiao Zhong, Dehai Xian, Xia Xiong, Junxiang Liu
Behçet's disease (BD) involves oxidative stress (OS) aggression and imbalanced oxidant/antioxidant status. Owing to its antioxidant property, allicin is proposed for treating BD. In this study, we aimed to investigate the efficacy and safety of allicin on patients with BD with mucocutaneous involvement. Twenty patients with active BD were treated with allicin for 12 weeks and followed up to 16 weeks. A clinical manifestations index and scoring system was the primary technique for efficacy evaluation at baseline and Week 4, 12, 16...
October 9, 2016: Dermatologic Therapy
https://www.readbyqxmd.com/read/27717500/vasculitis-induced-by-phenobarbital-with-cross-reactivity-to-carbamazepine
#18
Neila Fathallah, Chayma Ladhari, Raoudha Slim, Najet Ghariani, Badreddine Sriha, Chaker Ben Salem
Drug-associated immune-complex vasculitis induced by antiepileptics is a rare adverse drug reaction, more frequently reported with carbamazepine, valproic acid and phenytoin. Phenobarbital has not been previously reported to induce vasculitis. We report a cutaneous vasculitis induced by phenobarbital with cross-reactivity to carbamazepine in an 18-year-old epileptic patient. Carbamazepine and phenobarbital are both aromatic antiepileptic drugs with similarity in their chemical structure. Cross-reactivity is a frequently reported effect between these drugs following adverse skin reactions...
September 15, 2016: Thérapie
https://www.readbyqxmd.com/read/27688833/economic-burden-of-toxicities-associated-with-treating-metastatic-melanoma-in-the-united-states
#19
S Pinar Bilir, Qiufei Ma, Zhongyun Zhao, Elizabeth Wehler, Julie Munakata, Beth Barber
BACKGROUND: Little has been reported on the costs of managing the adverse events (AEs) associated with current therapies for patients with regional or distant metastatic melanoma. OBJECTIVES: To identify treatment-related AEs in patients with metastatic melanoma and to estimate the associated costs of treating these AEs in the United States. METHODS: A cost-estimation study for AEs associated with treatment of metastatic melanoma was conducted from 2012 to 2013 by identifying grades 3 and 4 AEs through the use of a comprehensive search of drug labels and English-language, published phase 2/3 studies in PubMed, conference abstracts, and the National Comprehensive Cancer Network guidelines...
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27680173/pancreatic-toxicity-as-an-adverse-effect-induced-by-meglumine-antimoniate-therapy-in-a-clinical-trial-for-cutaneous-leishmaniasis
#20
Marcelo Rosandiski Lyra, Sonia Regina Lambert Passos, Maria Inês Fernandes Pimentel, Sandro Javier Bedoya-Pacheco, Cláudia Maria Valete-Rosalino, Erica Camargo Ferreira Vasconcellos, Liliane Fatima Antonio, Mauricio Naoto Saheki, Mariza Mattos Salgueiro, Ginelza Peres Lima Santos, Madelon Noato Ribeiro, Fatima Conceição-Silva, Maria Fatima Madeira, Jorge Luiz Nunes Silva, Aline Fagundes, Armando Oliveria Schubach
American tegumentary leishmaniasis is an infectious disease caused by a protozoan of the genus Leishmania. Pentavalent antimonials are the first choice drugs for cutaneous leishmaniasis (CL), although doses are controversial. In a clinical trial for CL we investigated the occurrence of pancreatic toxicity with different schedules of treatment with meglumine antimoniate (MA). Seventy-two patients were allocated in two different therapeutic groups: 20 or 5 mg of pentavalent antimony (Sb5+)/kg/day for 20 or 30 days, respectively...
September 22, 2016: Revista do Instituto de Medicina Tropical de São Paulo
keyword
keyword
109299
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"